子宫癌或卵巢癌所致恶性肠梗阻:结局是否存在差异
回顾性分析两家机构2005年1月1日至2016年12月31日收治的子宫癌或卵巢癌复发/进展所致恶性肠梗阻患者,比较其治疗与结局。子宫癌组46例、卵巢癌组130例,接受住院化疗和手术等干预相似;恶性肠梗阻入院后中位总生存期子宫癌组57天 vs 卵巢癌组131天(p=0.0013)。接受手术或首次入院即转临终关怀者两组生存相似。
要点
- 恶性肠梗阻入院后中位总生存期子宫癌组57天 vs 卵巢癌组131天(p=0.0013)。
- 接受手术者子宫癌组182天 vs 卵巢癌组210天(p=0.6),无显著差异。
- 首次入院即转临终关怀者子宫癌组26天 vs 卵巢癌组38天(p=0.1),无显著差异。
核心结论
- 恶性肠梗阻预后相对较差。
- 卵巢癌与子宫癌患者中,干预措施包括手术或临终关怀者结局相似。
- 在未接受临终关怀的药物治疗患者中,子宫癌患者即使适合后续化疗,生存期仍更差。
- 这些发现可为该困难阶段的诊疗目标沟通提供信息,并将通过患者报告和定性数据得到增强。
研究设计与样本
- 回顾性病历审查,来自两家机构。
- 纳入2005年1月1日至2016年12月31日因复发/进展性子宫癌或卵巢癌所致恶性肠梗阻入院女性。
- 子宫癌组46例,卵巢癌组130例。
- 收集患者特征、恶性肠梗阻前后抗癌治疗、恶性肠梗阻管理策略及恶性肠梗阻后生存。
主要发现
- 子宫癌组与卵巢癌组接受住院化疗和手术等住院干预相似。
- 恶性肠梗阻入院后中位总生存期全部患者为105天,子宫癌组57天 vs 卵巢癌组131天(p=0.0013),子宫癌组更短。
- 接受手术者子宫癌组182天 vs 卵巢癌组210天(p=0.6),无显著差异。
- 首次入院即转临终关怀者子宫癌组26天 vs 卵巢癌组38天(p=0.1),无显著差异。
- 出院后化疗率子宫癌组37% vs 卵巢癌组50%(p=0.12),无显著差异;接受化疗者子宫癌组151天 vs 卵巢癌组225天(p=0.03),子宫癌组仍更短。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe and compare treatments and outcomes of patients with malignant bowel obstructions (MBO) due to uterine or ovarian cancer. METHODS: Retrospective chart review from two institutions of women admitted 1/1/2005-12/31/2016 with a MBO from recurrent/progressive uterine or ovarian cancer. Data collected includes patient characteristics, cancer-directed treatments before and after MBO, MBO management strategies, and survival after MBO. RESULTS: Women with MBO from uterine cancer (n = 46) and ovarian cancer (n = 130) underwent similar inpatient interventions such as inpatient chemotherapy and surgery. Median overall survival (OS) after admission for MBO for all patients was 105 days and was shorter for uterine cancer patients (57 vs 131 days, p = 0.0013). Uterine and ovarian cancer patients who had surgery had similar survival (182 vs 210 days, p = 0.6), as did those discharged on hospice from their first admission for MBO (26 vs 38 days, p = 0.1). Uterine and ovarian cancer patients had similar rates of post-discharge chemotherapy (37% vs 50%, p = 0.12), but uterine cancer patients who had chemotherapy still had shorter survival (151 vs 225 days, p = 0.03). CONCLUSIONS: MBO has a relatively poor prognosis. Ovarian and uterine cancer patients whose interventions included surgery or hospice had similar outcomes. Among patients managed medically without hospice, uterine cancer patients experienced worse survival, even when candidates for subsequent chemotherapy. Patient counseling regarding goals of care at this difficult juncture can be informed by these findings and will be enhanced by patient-reported and qualitative data on the patient experience with MBO.
引用
- Hoppenot C, Peters P, Cowan M, et al. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome? Gynecol Oncol. 2019. PMID: 31056111. doi:10.1016/j.ygyno.2019.04.681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。